Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.

Détails

ID Serval
serval:BIB_A0B57BD69CDC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.
Périodique
Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc
Auteur(s)
Volante M., Brizzi M.P., Faggiano A., La Rosa S., Rapa I., Ferrero A., Mansueto G., Righi L., Garancini S., Capella C., De Rosa G., Dogliotti L., Colao A., Papotti M.
ISSN
0893-3952 (Print)
ISSN-L
0893-3952
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
20
Numéro
11
Pages
1172-1182
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Typing somatostatin receptor expression in neuroendocrine tumors is of relevance to target somatostatin analogue-based diagnostic approach and treatment. The expanding use of immunohistochemistry to detect somatostatin receptors is to date not paralleled by an accurate methodological setting and standardized interpretation of the results. A multicentric study was designed to compare somatostatin receptor immunohistochemical expression with in vivo scintigraphic data and verify its usefulness in the clinical management of neuroendocrine tumors. After methodological setting by testing different somatostatin receptor antibodies, 107 cases of neuroendocrine tumors with available somatostatin receptor scintigraphy data and pathological material were retrospectively analyzed for somatostatin receptor types 2A, 3 and 5 immunohistochemical expression, and compared with scintigraphic images and, whenever available, with the clinical response to somatostatin analogue treatment. Restricting 'positive cases' to the presence of a membrane pattern of staining, an overall somatostatin receptor type 2A immunohistochemistry/somatostatin receptor scintigraphy agreement of 77% (chi2 test P<0.0001) was reached. Lower concordance ratios were detected in preoperative and metastatic tumor samples, possibly as a consequence of somatostatin receptor expression heterogeneity. Pure somatostatin receptor type 2A cytoplasmic staining showed poor correlation with somatostatin receptor scintigraphy (54% concordance rate). The immunohistochemical detection of somatostatin receptor types 3 and 5, which showed almost exclusively a cytoplasmic pattern, did not improve the concordance with scintigraphic data. In a pilot series, somatostatin receptor type 2A immunohistochemistry correlated with clinical response in 75% of cases. In conclusion, we propose a scoring system for somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors correlated with in vivo data, based on the evidence that only membrane (rather that cytoplasmic) staining should be considered for a reliable, standardized and clinically relevant report.
Mots-clé
Humans, Immunohistochemistry, Neuroendocrine Tumors/drug therapy, Neuroendocrine Tumors/metabolism, Pilot Projects, Radionuclide Imaging, Receptors, Somatostatin/metabolism, Sensitivity and Specificity, Somatostatin/analogs & derivatives, Somatostatin/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/09/2016 14:39
Dernière modification de la notice
20/08/2019 15:06
Données d'usage